A Belatacept Compassionate Use Study for Patients With a Kidney Transplant

Summary

To make belatacept available for recipients of a renal allograft who are currently intolerant to or have contraindications to CNIs and/or m-TOR inhibitors and are either: * unable to construct an adequate immunosuppression regimen due to nonrenal toxicity / contraindication (and withdrawing the causative agent would lead to renal graft loss) OR * at imminent risk of losing the allograft kidney due to nephrotoxicity and have no other options for renal replacement therapy

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications

No indication recorded.